Examining the impact of excessive daytime sleepiness on utility scores in patients with obstructive sleep apnoea and/or narcolepsy in five European countries

被引:6
|
作者
Cambron-Mellott, M. Janelle [1 ]
Mettam, Sam [2 ]
Li, Vicky W. [1 ]
Rowland, John C. [1 ]
Castro, JeanPierre Coaquira [3 ]
机构
[1] Cerner Enviza, Malvern, PA USA
[2] Jazz Pharmaceut, Oxford, England
[3] Jazz Pharmaceut, Palo Alto, CA USA
关键词
Health states utilities; Excessive daytime sleepiness; Obstructive sleep apnoea; Narcolepsy; Epworth Sleepiness Scale; QUALITY-OF-LIFE; GENERAL-POPULATION; HEART HEALTH; PREVALENCE; HYPOPNEA; SYMPTOMS;
D O I
10.1186/s12883-022-02827-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Excessive daytime sleepiness (EDS) is a cardinal symptom of narcolepsy and affects many patients with obstructive sleep apnoea (OSA). EDS is associated with reduced quality of life, increased accident risk, and poor workplace performance. Given the impact of EDS, the ability to predict health-related utility from sleepiness is valuable for examining the cost effectiveness of novel treatments. The aim of this study was to examine the association between EDS and EQ-5D in patients with OSA and/or narcolepsy by modelling EQ-5D utility scores from Epworth Sleepiness Scale (ESS) scores. Methods Data were obtained from the Europe 2016/2017 National Health and Wellness Survey, an online, general population survey, designed to represent the age and gender composition of each country's adult population. Analyses included 2,348 patients self-reporting symptomatic and diagnosed OSA (n = 2,277), narcolepsy (n = 48), or both (n = 23). Multivariable models were used to examine ESS as a predictor of EQ-5D utility while adjusting for covariates of interest. Results were validated following the National Institute for Health and Care Excellence Decision Support Unit guidelines for predictive modelling. Results Utility decreased as EDS severity increased (no EDS: 0.711 +/- 0.251, mild: 0.685 +/- 0.261, moderate: 0.643 +/- 0.268, severe: 0.559 +/- 0.323). Whereas participants with only OSA or only narcolepsy did not differ in utility, those with both conditions had lower scores (0.685 +/- 0.266 and 0.627 +/- 0.325 vs. 0.439 +/- 0.340, respectively). Piecewise linear regression identified a single breakpoint at ESS score of 11.29. In the final model, for each point increase in ESS score, the corresponding decrease in EQ-5D utility was larger among patients with ESS scores >= 12 compared to patients with ESS scores <= 11 (model slopes: -0.0131 vs. -0.0026, respectively). Findings from the validation sample confirmed these results. Conclusions This study demonstrates the impact of sleepiness on quality of life (QoL) and its negative impact irrespective of sleep condition (OSA or narcolepsy). The breakpoint identified is relatively consistent with the established ESS cutoff score >= 11, which demarcates pathological sleepiness. Furthermore, as EDS severity worsens (increases) on the ESS, the impact on QoL is greater.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Excessive daytime sleepiness as a risk factor for obstructive sleep apnoea among public transport drivers: A cross-sectional study
    Asha, C. L.
    Varma, N. K. Sapna
    Prabha, Rahul D.
    Ajith, V. V.
    INDIAN JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2023, 27 (01) : 21 - 25
  • [22] Management options for excessive daytime sleepiness in patients with obstructive sleep apnea
    Bonsignore, Maria R.
    Fanfulla, Francesco
    Ingrao, Pietro
    Lombardo, Simone
    Tondo, Pasquale
    Lo Nano, Vanessa
    Lombardi, Carolina
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2025, 19 (04) : 325 - 345
  • [23] Subjective apnoea symptoms are associated with daytime sleepiness in patients with moderate and severe obstructive sleep apnoea: a retrospective study
    Ryu, H. S.
    Lee, S. A.
    Lee, G. H.
    Chung, Y. S.
    Kim, W. S.
    CLINICAL OTOLARYNGOLOGY, 2016, 41 (04) : 395 - 401
  • [24] Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea
    Idris, Iskandar
    Abdulla, Haitham
    Tilbrook, Sean
    Dean, Roy
    Ali, Nabeel
    JOURNAL OF SLEEP RESEARCH, 2013, 22 (01) : 70 - 75
  • [25] Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials
    Subedi, Roshan
    Singh, Rajshree
    Thakur, Rahul Kumar
    Bibek, K. C.
    Jha, Divyanshu
    Ray, Barun Kumar
    SLEEP MEDICINE, 2020, 75 : 510 - 521
  • [26] Low sleep quality and daytime sleepiness in obese patients without obstructive sleep apnoea syndrome
    Resta, O
    Barbaro, MPF
    Bonfitto, P
    Giliberti, T
    Depalo, A
    Pannacciulli, N
    De Pergola, G
    JOURNAL OF INTERNAL MEDICINE, 2003, 253 (05) : 536 - 543
  • [27] Different components of excessive daytime sleepiness and the change with positive airway pressure treatment in patients with obstructive sleep apnea: Results from the Icelandic Sleep Apnea Cohort (ISAC)
    Thorarinsdottir, Elin H.
    Janson, Christer
    Aspelund, Thor
    Benediktsdottir, Bryndis
    Juliusson, Sigurour
    Gislason, Thorarinn
    Kuna, Samuel T.
    Pack, Allan, I
    Keenan, Brendan T.
    JOURNAL OF SLEEP RESEARCH, 2022, 31 (03)
  • [28] Factors associated with excessive daytime sleepiness in patients with severe obstructive sleep apnea
    John H. Jacobsen
    Lei Shi
    Babak Mokhlesi
    Sleep and Breathing, 2013, 17 : 629 - 635
  • [29] Machine learning-Based model for prediction of Narcolepsy Type 1 in Patients with Obstructive Sleep Apnea with Excessive Daytime Sleepiness
    Pan, Yuanhang
    Zhao, Di
    Zhang, Xinbo
    Yuan, Na
    Yang, Lei
    Jia, Yuanyuan
    Guo, Yanzhao
    Chen, Ze
    Wang, Zezhi
    Qu, Shuyi
    Bao, Junxiang
    Liu, Yonghong
    NATURE AND SCIENCE OF SLEEP, 2024, 16 : 639 - 652
  • [30] Factors associated with excessive daytime sleepiness in patients with severe obstructive sleep apnea
    Jacobsen, John H.
    Shi, Lei
    Mokhlesi, Babak
    SLEEP AND BREATHING, 2013, 17 (02) : 629 - 635